A major evidence review has compared dozens of treatments for bipolar disorder across its different mood phases and paired the findings with a new online decision tool for clinicians and patients. The analysis, published in The BMJ, pulls together data on how well each option works and how strong the supporting science is.
The authors stress that many people with bipolar disorder abandon treatment because they feel it is ineffective, intolerable or imposed without their input. By organizing the latest research into a user-friendly platform, they hope to support shared decision-making and improve long-term outcomes. The tool is designed to be updated as new studies appear.
How the review was conducted
The project synthesizes 77 existing meta-analyses, which themselves combine results from multiple clinical trials. Researchers graded each intervention on the certainty of the evidence and on three key outcomes: symptom improvement, treatment response and remission.
Crucially, treatments were evaluated separately for depressive, manic and maintenance phases of bipolar disorder. This matters because a drug that helps during mania may be less effective, or even risky, during depression, and vice versa. The platform is intended to reflect these phase-specific differences in real time.
Best-supported options for bipolar depression
For adults in a depressive episode, several atypical antipsychotics emerged with moderate-to-high certainty of benefit across all three efficacy measures. Cariprazine, lurasidone, olanzapine and quetiapine showed consistent effects on symptoms, response and remission when compared with placebo or standard care.
These findings align with existing treatment guidelines that position certain atypical antipsychotics, sometimes in combination with mood stabilizers, as first-line options for bipolar depression. However, the review does not override the need to weigh side effects, co-existing conditions and patient preferences before prescribing.
What works best for mania?
During manic phases, the review found strong evidence for haloperidol and risperidone, which produced the largest improvements in manic symptoms and response rates. The certainty of evidence was high, suggesting that their benefits are well established across multiple studies.
Risperidone’s long-acting injectable formulation may offer an additional advantage for some patients, helping to stabilize mood between acute episodes. Long-acting forms can support continuity of care for people who have difficulty taking medications consistently by mouth.
An unexpected candidate, tamoxifen, demonstrated very large effects in early trials for mania. Yet this hormone therapy, traditionally used in breast cancer, is not approved for bipolar disorder and may not suit many patients. The review highlights it as promising but emphasizes that more rigorous research and safety data are needed.
Maintaining stability between episodes
In the maintenance phase, where the goal is to prevent new depressive or manic episodes, the analysis drew attention to non-drug strategies as well as medications. Group psychoeducation, added to usual pharmacological care, showed at least moderate-certainty evidence for reducing the risk of any type of episode, albeit with small effect sizes.
The authors suggest that structured education groups may help people better understand their illness, recognize early warning signs, stabilize daily routines and adhere to medication. Cognitive behavioral therapy also appeared to support symptom control and reduce relapse, though the strength of evidence varied by outcome.
Medication remains central to maintenance treatment, particularly mood stabilizers and certain atypical antipsychotics. However, the review argues that combining drug therapy with tailored psychological interventions is likely to produce better long-term control than medication alone.
A tool to support shared decisions
The new web-based platform translates this complex evidence into an interactive resource for clinicians and patients. Users can explore which options have the best balance of efficacy and certainty for each phase of bipolar disorder, while also factoring in preferences about side effects and treatment burden.
Researchers describe the project as a “living review,” meaning the evidence base will be updated as new trials and meta-analyses are published. The ultimate test will be whether the tool improves real-world prescribing patterns, adherence and quality of life compared with usual care.
Experts caution that even the most comprehensive meta-analysis cannot predict exactly how an individual will respond. The findings are designed to guide, not replace, clinical judgment and personalized care. Anyone considering changes to their treatment plan should do so in close consultation with a qualified mental health professional.
The study also underscores the urgency of early, consistent care for bipolar disorder, which is associated with elevated risks of suicide, cardiovascular disease and premature mortality. Improving access to effective medications, psychological therapies and informed decision support could help narrow that gap over time.
